{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:24:48Z","timestamp":1791951888525,"version":"4.3.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"DOI":"10.1186\/s13014-026-02799-9","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:33:17Z","timestamp":1771000397000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Magnetic resonance-guided simultaneous multi-fo\u200bcal adaptive radiotherapy for prostate, pElvis & metastases (MRgSMART-PEM) in prostate cancer: a prospective phase II study"],"prefix":"10.1186","volume":"21","author":[{"given":"Meng","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Rui","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Ling","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Long","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Qiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Wen","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Lian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye-Xiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nian-Zeng","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning-Ning","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"2799_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"2799_CR2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/CU9.0000000000000173","volume":"17","author":"M Massanova","year":"2023","unstructured":"Massanova M, Vere R, Robertson S, et al. Clinical and prostate multiparametric magnetic resonance imaging findings as predictors of general and clinically significant prostate cancer risk: A retrospective single-center study. Curr Urol. 2023;17:147\u201352.","journal-title":"Curr Urol"},{"key":"2799_CR3","first-page":"47","volume":"4","author":"B Han","year":"2024","unstructured":"Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4:47\u201353.","journal-title":"J Natl Cancer Cent"},{"key":"2799_CR4","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1097\/CU9.0000000000000217","volume":"18","author":"J Jaipuria","year":"2024","unstructured":"Jaipuria J, Kaur I, Doja MN, et al. Comparative analysis of real-world data of frequent treatment sequences in metastatic prostate cancer. Curr Urol. 2024;18:104\u20139.","journal-title":"Curr Urol"},{"key":"2799_CR5","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392:2353\u201366.","journal-title":"Lancet"},{"key":"2799_CR6","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.20.00818","volume":"38","author":"DA Palma","year":"2020","unstructured":"Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: Long-Term results of the SABR-COMET phase II randomized trial. J Clin Oncol. 2020;38:2830\u20138.","journal-title":"J Clin Oncol"},{"key":"2799_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","volume":"76","author":"S Burdett","year":"2019","unstructured":"Burdett S, Boev\u00e9 LM, Ingleby FC, et al. Prostate radiotherapy for metastatic Hormone-sensitive prostate cancer: A STOPCAP systematic review and Meta-analysis. Eur Urol. 2019;76:115\u201324.","journal-title":"Eur Urol"},{"key":"2799_CR8","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","volume":"17","author":"D Dearnaley","year":"2016","unstructured":"Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17:1047\u201360.","journal-title":"Lancet Oncol"},{"key":"2799_CR9","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","volume":"34","author":"WR Lee","year":"2016","unstructured":"Lee WR, Dignam JJ, Amin MB, et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with Low-Risk prostate cancer. J Clin Oncol. 2016;34:2325\u201332.","journal-title":"J Clin Oncol"},{"key":"2799_CR10","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","volume":"35","author":"CN Catton","year":"2017","unstructured":"Catton CN, Lukka H, Gu CS, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol. 2017;35:1884\u201390.","journal-title":"J Clin Oncol"},{"key":"2799_CR11","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S1470-2045(16)30070-5","volume":"17","author":"L Incrocci","year":"2016","unstructured":"Incrocci L, Wortel RC, Alemayehu WG, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2016;17:1061\u20139.","journal-title":"Lancet Oncol"},{"key":"2799_CR12","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","volume":"394","author":"A Widmark","year":"2019","unstructured":"Widmark A, Gunnlaugsson A, Beckman L, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019;394:385\u201395.","journal-title":"Lancet"},{"key":"2799_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.radonc.2013.08.030","volume":"109","author":"CR King","year":"2013","unstructured":"King CR, Freeman D, Kaplan I, et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol. 2013;109:217\u201321.","journal-title":"Radiother Oncol"},{"key":"2799_CR14","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","volume":"20","author":"DH Brand","year":"2019","unstructured":"Brand DH, Tree AC, Ostler P, et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2019;20:1531\u201343.","journal-title":"Lancet Oncol"},{"key":"2799_CR15","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","volume":"391","author":"N van As","year":"2024","unstructured":"van As N, Griffin C, Tree A, et al. Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer. N Engl J Med. 2024;391:1413\u201325.","journal-title":"N Engl J Med"},{"key":"2799_CR16","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.ijrobp.2010.05.008","volume":"79","author":"C Peng","year":"2011","unstructured":"Peng C, Ahunbay E, Chen G, et al. Characterizing interfraction variations and their dosimetric effects in prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2011;79:909\u201314.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2799_CR17","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.ijrobp.2009.12.053","volume":"79","author":"BL King","year":"2011","unstructured":"King BL, Butler WM, Merrick GS, et al. Electromagnetic transponders indicate prostate size increase followed by decrease during the course of external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2011;79:1350\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2799_CR18","first-page":"54","volume":"18","author":"D Winkel","year":"2019","unstructured":"Winkel D, Bol GH, Kroon PS, et al. Adaptive radiotherapy: the Elekta unity MR-linac concept. Clin Transl Radiat Oncol. 2019;18:54\u20139.","journal-title":"Clin Transl Radiat Oncol"},{"key":"2799_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.phro.2019.07.002","volume":"11","author":"MD den Hartogh","year":"2019","unstructured":"den Hartogh MD, de Boer HCJ, de Groot-van EN, Breugel, et al. Planning feasibility of extremely hypofractionated prostate radiotherapy on a 1.5 T magnetic resonance imaging guided linear accelerator. Phys Imaging Radiat Oncol. 2019;11:16\u201320.","journal-title":"Phys Imaging Radiat Oncol"},{"key":"2799_CR20","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.radonc.2020.06.044","volume":"151","author":"DM de Muinck Keizer","year":"2020","unstructured":"de Muinck Keizer DM, Kerkmeijer LGW, Willigenburg T, et al. Prostate intrafraction motion during the Preparation and delivery of MR-guided radiotherapy sessions on a 1.5T MR-Linac. Radiother Oncol. 2020;151:88\u201394.","journal-title":"Radiother Oncol"},{"key":"2799_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13014-020-01510-w","volume":"15","author":"F Alongi","year":"2020","unstructured":"Alongi F, Rigo M, Figlia V, et al. 1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment. Radiat Oncol. 2020;15:69.","journal-title":"Radiat Oncol"},{"key":"2799_CR22","doi-asserted-by":"crossref","unstructured":"Kishan AU, Ma TM, Lamb JM, et al. Magnetic resonance Imaging\u2013Guided vs computed Tomography\u2013Guided stereotactic body radiotherapy for prostate cancer. JAMA Oncol. 2023;9.","DOI":"10.1001\/jamaoncol.2022.6558"},{"key":"2799_CR23","unstructured":"NCCN Clinical Practice. Guidelines in Oncology Prostate Cancer. https:\/\/www.nccn.org\/guidelines\/category_1#prostate"},{"key":"2799_CR24","doi-asserted-by":"publisher","first-page":"1039901","DOI":"10.3389\/fonc.2023.1039901","volume":"13","author":"LR Gao","year":"2023","unstructured":"Gao LR, Tian Y, Wang MS, et al. Assessment of delivered dose in prostate cancer patients treated with ultra-hypofractionated radiotherapy on 1.5-Tesla MR-Linac. Front Oncol. 2023;13:1039901.","journal-title":"Front Oncol"},{"key":"2799_CR25","first-page":"51","volume":"10","author":"L Gao","year":"2024","unstructured":"Gao L, Wei R, Qin S, et al. Adaptive ultra-hypofractionated whole-pelvic radiotherapy in high-risk and very high-risk prostate cancer on 1.5-Tesla MR-Linac: estimated delivered dose and early toxicity results. Chronic Dis Transl Med. 2024;10:51\u201361.","journal-title":"Chronic Dis Transl Med"},{"key":"2799_CR26","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ijrobp.2008.08.002","volume":"74","author":"CA Lawton","year":"2009","unstructured":"Lawton CA, Michalski J, El-Naqa I, et al. RTOG GU radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2009;74:383\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2799_CR27","doi-asserted-by":"crossref","unstructured":"The International Commission on Radiation Units and Measurements. Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT). ICRU report 83. J ICRU. 2010;10.","DOI":"10.1093\/jicru\/ndq002"},{"key":"2799_CR28","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.ijrobp.2024.04.070","volume":"120","author":"J Zhu","year":"2024","unstructured":"Zhu J, Li X, Huang M, et al. Application of Recombinant human superoxide dismutase in radical concurrent chemoradiotherapy for cervical cancer to prevent and treat Radiation-induced acute rectal injury: A Multicenter, Randomized, Open-label, prospective trial. Int J Radiat Oncol Biol Phys. 2024;120:720\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2799_CR29","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/S0022-5347(17)36966-5","volume":"148","author":"MJ Barry","year":"1992","unstructured":"Barry MJ, Fowler FJ Jr., O\u2019Leary MP, et al. The American urological association symptom index for benign prostatic hyperplasia. The measurement committee of the American urological association. J Urol. 1992;148:1549\u201357. discussion 1564.","journal-title":"J Urol"},{"key":"2799_CR30","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.urology.2010.01.027","volume":"76","author":"KM Szymanski","year":"2010","unstructured":"Szymanski KM, Wei JT, Dunn RL, et al. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology. 2010;76:1245\u201350.","journal-title":"Urology"},{"key":"2799_CR31","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/S0090-4295(97)00459-7","volume":"50","author":"P Esper","year":"1997","unstructured":"Esper P, Mo F, Chodak G, et al. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology. 1997;50:920\u20138.","journal-title":"Urology"},{"key":"2799_CR32","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365\u201376.","journal-title":"J Natl Cancer Inst"},{"key":"2799_CR33","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/sj.ijir.3900472","volume":"11","author":"RC Rosen","year":"1999","unstructured":"Rosen RC, Cappelleri JC, Smith MD, et al. Development and evaluation of an abridged, 5-item version of the international index of erectile function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11:319\u201326.","journal-title":"Int J Impot Res"},{"key":"2799_CR34","doi-asserted-by":"crossref","unstructured":"Poon DMC, Yuan J, Wong OL, et al. 1.5T magnetic Resonance-Guided stereotactic body radiotherapy for localized prostate cancer: preliminary clinical results of Clinician- and Patient-Reported outcomes. Cancers (Basel). 2021;13.","DOI":"10.3390\/cancers13194866"},{"key":"2799_CR35","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.euo.2020.05.007","volume":"4","author":"SU Tetar","year":"2021","unstructured":"Tetar SU, Bruynzeel AME, Oei SS, et al. Magnetic Resonance-guided stereotactic radiotherapy for localized prostate cancer: final results on Patient-reported outcomes of a prospective phase 2 study. Eur Urol Oncol. 2021;4:628\u201334.","journal-title":"Eur Urol Oncol"},{"key":"2799_CR36","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.ijrobp.2015.02.046","volume":"92","author":"G Bauman","year":"2015","unstructured":"Bauman G, Ferguson M, Lock M, et al. A phase 1\/2 trial of brief androgen suppression and stereotactic radiation therapy (FASTR) for High-Risk prostate cancer. Int J Radiat Oncol Biol Phys. 2015;92:856\u201362.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2799_CR37","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/j.ijrobp.2018.07.2005","volume":"102","author":"HB Musunuru","year":"2018","unstructured":"Musunuru HB, D\u2019Alimonte L, Davidson M, et al. Phase 1\u20132 study of stereotactic ablative radiotherapy including regional lymph node irradiation in patients with High-Risk prostate cancer (SATURN): early toxicity and quality of life. Int J Radiat Oncol Biol Phys. 2018;102:1438\u201347.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2799_CR38","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.clon.2020.10.019","volume":"33","author":"T Telkhade","year":"2021","unstructured":"Telkhade T, Murthy V, Kanala TS, et al. Safety and efficacy of Ultra-hypofractionation in Node-positive prostate cancer. Clin Oncol. 2021;33:172\u201380.","journal-title":"Clin Oncol"},{"key":"2799_CR39","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1748-717X-9-22","volume":"9","author":"A Gunnlaugsson","year":"2014","unstructured":"Gunnlaugsson A, Kjell\u00e9n E, Hagberg O, et al. Change in prostate volume during extreme hypo-fractionation analysed with MRI. Radiat Oncol. 2014;9:22.","journal-title":"Radiat Oncol"},{"key":"2799_CR40","doi-asserted-by":"crossref","unstructured":"Poon DMC, Yuan J, Yang B, et al. A prospective study of stereotactic body radiotherapy (SBRT) with concomitant Whole-Pelvic radiotherapy (WPRT) for High-Risk localized prostate cancer patients using 1.5 Tesla magnetic resonance guidance: the preliminary clinical outcome. Cancers (Basel). 2022;14.","DOI":"10.3390\/cancers14143484"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-026-02799-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-026-02799-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-026-02799-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:01:08Z","timestamp":1771509668000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13014-026-02799-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2799"],"URL":"https:\/\/doi.org\/10.1186\/s13014-026-02799-9","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"29 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). This clinical research was approved by the Ethics Committee of National Cancer Center\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (Approval No.: 20\/121\u20132317). All participants signed informed consent forms.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent to be enrolled in this trial and data for publication had been collected for all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}